As far as MBC is concerned, it can be stated that, to date, it is not necessary to perform NGS multigene analysis on tumor tissue for the choice of the first line of therapy, since the BRCA1/BRCA2 status can be determined by germline DNA sequencing, PD-L1 status by immunohistochemistry and PIK3CA by tumor tissue PCR. Here, PIK3CA is linked to neoplasm.